

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
 Witness Disclosure Requirement – “Truth in Testimony”  
 Required by House Rule XI, Clause 2(g)(5)

<b>1. Your Name:</b> Dr. Nabarun Dasgupta		
<b>2. Your Title:</b> Senior Scientist and Innovation Fellow		
<b>3. The Entity(ies) You are Representing:</b> University of North Carolina at Chapel Hill		
<b>4. Are you testifying on behalf of the Federal, or a State or local government entity? (If “Yes,” skip Item 5 and Item 6.)</b>	Yes	
<b>5. Grants, Contracts, and Payments</b>		
<p style="text-align: center;"><b>a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b></p> <p>The University of North Carolina is considered a state government entity. However, we have received research funding directly relevant to the matter of the hearing.</p> <p>1. Characterization of the impact of xylazine and dexmedetomidine: binding profile, addictive behaviors, physiology, and wound development Source: US Food and Drug Administration (FDA) Triangle CERSI \$1,449,894</p> <p>2. Buprenorphine Initiation and Dosing to Reduce Non-fatal Overdoses and Prevent Mortality Evaluation of Buprenorphine Initiation and Dosing to Reduce Non-fatal Overdoses and Prevent Mortality Source: US Food and Drug Administration (FDA) via Triangle CERSI \$450,532.63</p> <p>3. Exploring Intravenous Injection Behaviors, Knowledge, and Drug Preferences of Individuals Injecting Prescription Opioids and/or Prescription Stimulants Source: US Food and Drug Administration (FDA)/subaward from RTI International \$246,188.88</p> <p>4. Opioid Data Lab: Understanding Overdose Risk Through Innovative Epidemiology and Analytical Chemistry Source: US Food and Drug Administration (FDA) \$ 4,579,845.00</p> <p style="text-align: center;"><b>b. Please list any <u>contracts or payments originating with a foreign government</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.</b></p> <p style="text-align: center;">NONE</p>		
<b>6. Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing?</b>	No	
<b>7. Please attach your curriculum vitae to your completed disclosure form.</b>		

**Signature:**  \_\_\_\_\_

**Date:** \_\_\_\_\_ March 23, 2026 \_\_\_\_\_

## INSTRUCTIONS FOR COMPLETING THE TRUTH-IN-TESTIMONY DISCLOSURE FORM

***In General.*** The attached form is intended to assist witnesses appearing before the Committee on Energy and Commerce in complying with Rule XI, clause 2(g)(5) of the Rules of the House of Representatives, which provides:

(B) In the case of a witness appearing in a non-governmental capacity, a written statement of proposed testimony shall include—(i) a curriculum vitae; (ii) a disclosure of any Federal grants or contracts, or contracts, grants, or payments originating with a foreign government, received during the past 36 months by the witness or by an entity represented by the witness and related to the subject matter of the hearing; and (iii) a disclosure of whether the witness is a fiduciary (including, but not limited to, a director, officer, advisor, or resident agent) of any organization or entity that has an interest in the subject matter of the hearing. (C) The disclosure referred to in subdivision (B)(ii) shall include—(i) the amount and source of each Federal grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing; and (ii) the amount and country of origin of any payment or contract related to the subject matter of the hearing originating with a foreign government. (D) Such statements, with appropriate redactions to protect the privacy or security of the witness, shall be made publicly available in electronic form 24 hours before the witness appears to the extent practicable, but not later than one day after the witness appears.

### **Please complete the form in accordance with these directions.**

1. ***Name (Item 1 on the form).*** Please provide the name of the witness.
2. ***Title (Item 2 on the form).*** Please provide the title of the witness.
3. ***Entity(ies) (Item 3 on the form).*** Please identify the entity(ies) on whose behalf the witness is testifying.
4. ***Governmental Entity (Item 4).*** Please check the box indicating whether or not the witness is testifying on behalf of a government entity, such as a Federal department or agency, or a State or local department, agency, or jurisdiction. Trade or professional associations of public officials are not considered to be governmental entities. If you answer “Yes” to Item 4, please skip Item 5.a, Item 5.b, and Item 6.
5. ***Grants and Contracts***
  - a. ***(Item 5.a).*** Please list any Federal grants or contracts that you or the entity(ies) you represent have received on or after January 1, 2023. For each such grant (or subgrant thereof) or contract (or subcontract thereof) related to the subject matter of the hearing, please include the amount and source of each. Only grants, contracts, or payments related to the hearing must be listed.
  - b. ***(Item 5.b).*** Please list any contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2023. For each such contract or payment related to the subject matter of the hearing, please include the amount and country of origin. Only grants, contracts, or payments related to the hearing must be listed.
6. ***Fiduciary Capacity (Item 6).*** Please check the box indicating whether or not the witness is a fiduciary of **any** organization or entity with an interest in the subject matter of the hearing. This includes, but is not limited to, serving as a director, officer, advisor, or resident agent of an entity with an interest in the hearing.

7. ***Curriculum Vitae (Item 7).*** Please attach your CV to your completed disclosure form.
8. ***Submission.*** Please sign and date the form in the appropriate place. Please submit this form with your written testimony. Please note that under the Committee's rules, copies of a written statement of your proposed testimony must be submitted before the hearing commencements. To the greatest extent practicable, please also provide a copy in electronic format according to the accompanying Electronic Format Guidelines.